The short version of purity fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-06-27 and is reviewed periodically as new material appears.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH analog, not a steroid |
| Backbone length | 29 amino acids | Based on GRF(1-29) |
| Substitutions | Four positions | D-Ala2, Gln8, Ala15, Leu27 |
| Appearance | White to off-white powder | Typical lyophilized research material |
| Common synonyms | Modified GRF(1-29) | Usage varies between sources |
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Beta-thalassemia (β-thalassemia) is an inherited blood disorder, a form of thalassemia resulting in variable outcomes ranging from clinically asymptomatic to severely anemic individuals. It is caused by reduced or absent synthesis of the beta chains of hemoglobin, the molecule that carries oxygen in the blood. Symptoms depend on the extent to which hemoglobin is deficient, and include anemia, pallor, tiredness, enlargement of the spleen, jaundice, and gallstones. In severe cases death ensues. Beta thalassemia occurs due to a mutation of the HBB gene leading to deficient production of the hemoglobin subunit beta-globin; the severity of the disease depends on the nature of the mutation, and whether or not the mutation is homozygous. The body's inability to construct beta-globin leads to reduced or zero production of adult hemoglobin thus causing anemia. The other component of hemoglobin, alpha-globin, accumulates in excess leading to ineffective production of red blood cells, increased hemolysis, and iron overload. Diagnosis is by checking the medical history of near relatives, microscopic examination of blood smear, ferritin test, hemoglobin electrophoresis, and DNA sequencing. As an inherited condition, beta thalassemia cannot be prevented although genetic counselling of potential parents prior to conception can propose the use of donor sperm or eggs. Patients may require repeated blood transfusions throughout life to maintain sufficient hemoglobin levels; this in turn may lead to severe problems associated with iron overload.
== Discovery == NAPE-PLD is an enzyme activity - a phospholipase, acting on phospholipids found in the cell membrane. It is not homology but the chemical outcome of its activity that classes it as phospholipase D. The enzymatic activity was discovered and characterized in a series of experiments culminating in the 2004 publication of a biochemical purification scheme from which peptide sequencing could be accomplished. Researchers homogenized (finely ground) hearts from 150 rats and subjected the resulting crude lysate to sucrose sedimentation at 105,000 x g to separate the cell membranes from the remainder of the cell. The integral membrane proteins were then solubilized using octyl glucoside and subjected to four column chromatography steps (HiTrap SP HP cation-exchange column, HiTrap Q anion-exchange column, HiTrap Blue affinity column, Bio-Gel HTP hydroxyapatite column). Each of these separates the different types of membrane proteins into different sample containers when the proteins are eluted from the column over time, and by measuring the activity of samples in each container it was possible to track which ones received the active enzyme. Measurement of the enzyme activity was done by thin layer chromatography of a radioactive substrate sensitive to the NAPE-PLD enzymatic activity: Cleavage of the substrate affected where it appeared on the plate when the radiation was detected on a bioimaging analyzer.
Chemicals Hydroxylamine Base analogues (e.g., Bromodeoxyuridine (BrdU)) Alkylating agents (e.g., N-ethyl-N-nitrosourea (ENU). These agents can mutate both replicating and non-replicating DNA. In contrast, a base analogue can mutate the DNA only when the analogue is incorporated in replicating the DNA. Each of these classes of chemical mutagens has certain effects that then lead to transitions, transversions, or deletions. Agents that form DNA adducts (e.g., ochratoxin A) DNA intercalating agents (e.g., ethidium bromide) DNA crosslinkers Oxidative damage Nitrous acid converts amine groups on A and C to diazo groups, altering their hydrogen bonding patterns, which leads to incorrect base pairing during replication. Radiation Ultraviolet light (UV) (including non-ionizing radiation). Two nucleotide bases in DNA—cytosine and thymine—are most vulnerable to radiation that can change their properties. UV light can induce adjacent pyrimidine bases in a DNA strand to become covalently joined as a pyrimidine dimer. UV radiation, in particular longer-wave UVA, can also cause oxidative damage to DNA. Ionizing radiation. Exposure to ionizing radiation, such as gamma radiation, can result in mutation, possibly resulting in cancer or death. Whereas in former times mutations were assumed to occur by chance, or induced by mutagens, molecular mechanisms of mutation have been discovered in bacteria and across the tree of life. As S.
The renovated park featured a great lawn, as well as hedges and later an iron fence that separated the park from the surrounding city streets. Two entrances each were added from 40th and 42nd Streets. As part of the project, 270 trees were placed around the park. Moses also placed the park's statues along 40th and 42nd Streets so as to block sight lines from these streets. To save money, the project hired workers from the Civil Works Administration, an unemployment relief program. The renovation was complete by late 1934, and after a short postponement, the park reopened that September 15. Parts of the park were closed in the late 1930s due to transit changes on Sixth Avenue; the elevated was torn down in 1938, and the construction of the underground Sixth Avenue subway line occurred around the same time. The Sixth Avenue subway opened in 1940. A New Yorker article remarked in 1936 that during the prior 14 years, "Bryant Park has been closed to the public [...] for half that time."
American biochemist, botanist, plant geneticist, and drosophilist W. Wallace Cleland (1930–2013). American biochemist at the University of Wisconsin–Madison known for work on enzyme kinetics and mechanism. Member Natl. Acad. Sci. USA. G. Marius Clore FRS (b. 1955). British-American biochemist at the NIH known for work in protein and nucleic acid structure determination by nuclear magnetic resonance spectroscopy. Member Natl. Acad. Sci. USA.
Sources: en.wikipedia.org
=== Lunar distance === Lunar distance (LD), the distance from the centre of Earth to the centre of the Moon, is a unit of measure in astronomy. The lunar distance is approximately 384,400 km (238,900 mi), or 1.28 light-seconds; this is roughly 30 times Earth's diameter. A little less than 400 lunar distances make up an astronomical unit.
=== Drinking water and products === In April 2024 EPA issued a final drinking water rule for PFOA, PFOS, GenX, PFBS, PFNA, and PFHxS. Public water systems must remove these six PFAS to near-zero levels by 2027. Grant funding is available from EPA to assist utilities in water testing and development of treatment systems. The State of New Jersey published drinking water standards for PFOA and PFOS in 2020. A standard for PFNA was published in 2018. This was the first state to publish PFAS standards in the absence of federal regulations. See U.S. state government actions. In 2018 the State of New York adopted drinking water standards of 10 ppt for PFOA and 10 ppt for PFOS, the most stringent such standards in the United States. The standards apply to public water systems and took effect in 2019 after a public comment period. Using information gained through a Freedom of Information Act request, in May 2018 it was learned that January 2018 emails between the EPA, the Office of Management and Budget, the Department of Defense, and the Department of Health and Human Services showed an effort to suppress the release of a draft report on the toxicology of PFOS and PFOA done by the Agency for Toxic Substances and Disease Registry. The report found that these chemicals endanger human health at a far lower level than EPA has previously called safe. After media accounts of the effort surfaced, the regional EPA administrator for Colorado denied that EPA had anything to do with suppressing the report. The report was released on June 21, 2018.
Anthropology & Education Quarterly. 13 (2): 133–148. doi:10.1525/aeq.1982.13.2.05x1830j. JSTOR 3216627. Spain, Victor; Scarlett, Janet; Houpt, Katherine (2004). "Long-term Risks and Benefits of Early-age Gonadectomy in Cats". Journal of the American Veterinary Medical Association. 224 (3): 372–379. doi:10.2460/javma.2004.224.372. PMID 14765796. Sturgess, Kit; Hurley, Karyl (2005). "Nutrition and Welfare". The Welfare of Cats. Animal Welfare. Vol. 3. Rochlitz. pp. 227–257. doi:10.1007/1-4020-3227-7_9. ISBN 1-4020-3226-9. Sunquist, Fiona; Sunquist, Mel (2014). The Wild Cat Book: Everything You Ever Wanted to Know About Cats. Chicago University. ISBN 978-0-226-14576-1. Tootle, John; Friedlander, Michael (1989). "Postnatal Development of the Spatial Contrast Sensitivity of X- and Y-cells in the Kittens Retinogeniculate Pathway". The Journal of Neuroscience. 9 (4). Journal of Neuroscience: 1325–1340. doi:10.1523/JNEUROSCI.09-04-01325.1989. PMC 6569875. PMID 2703879. Tsutsui, Toshihiko; Stabenfeldt, George (1993). "Biology of Ovarian Cycles, Pregnancy and Pseudo Pregnancy in the Domestic Cat". Journal of Reproduction and Fertility Supplement. 47: 29–35. PMID 8229938. Vandivert, Rita (1975). Understanding Animals as Pets. Illustrated Publishing. ISBN 978-0-7232-6118-6. Walls, Jerry (1991). Kittens as a New Pet. TFH Publications. ISBN 978-0-86622-614-1. Greco, D.S. (2014). Pediatric Nutrition. Veterinary Clinics of North America: Small Animal Practice. ISBN 978-0-32337-185-8.{{cite book}}: CS1 maint: publisher location (link)
Similarly to the findings with a strong CYP2D6 inhibitor, a pharmacogenomic clinical study with LSD found that LSD levels were 75% higher in people with non-functional CYP2D6 (poor metabolizers) compared to those with functional CYP2D6. Serotonin syndrome can be caused by combining psychedelics with other serotonergic drugs, including certain antidepressants, opioids, psychostimulants (e.g. MDMA), serotonin 5-HT1 receptor agonists (e.g. triptans), herbs or supplements, and others. However, there is said to be no risk of serotonin syndrome when psychedelics like LSD or psilocybin are taken while on SSRIs. The same is not true of ayahuasca, as ayahuasca also contains harmala alkaloids which act as MAOIs and can produce life-threatening serotonin toxicity when combined with SSRIs. A high rate of seizures has been reported when people on lithium have taken serotonergic psychedelics. In an analysis of online reports, 47% of 62 accounts reported seizures when a psychedelic was taken while on lithium. The mechanism of this interaction is unclear.
Sources: en.wikipedia.org
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.
The original material included a linker that binds serum albumin. A later variant removed that linker to reduce the duration of action. Catalogs and papers did not consistently adopt separate names, so both remain widely labeled with the same term.
The amino acid sequence and the presence or absence of the linker group. Mass measured by spectrometry gives an independent check that separates the two forms.
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.